Petronas taps Tanjung for Bayan offshore production unit

first_imgMalaysia’s oilfield services provider Tanjung Offshore Services (TOS) has received a letter of award from Petronas Carigali for the leasing, operating, and maintenance of a mobile offshore production unit (MOPU) for the Bayan Gas Development Project Phase 2.Petronas twin towers in Malaysia; Source: Unsplash; Author: Vlad ShapochnikovTanjung said on Thursday that the contract was won by a wholly-owned subsidiary of the company and its consortium partner VME Process Systems Malaysia on January 30.The company added that the value of the contract was based on the contract price as stipulated in the letter of award.The effective date of the contract is February 1 and the acceptance date is 27 months from the effective date. The time charter period is for ten years from the acceptance date.According to previous announcements by Petronas Carigali, phase two of the Bayan gas redevelopment in the Balingian PSC offshore Sarawak, Malaysia, will entail drilling of four wells at the existing BYDP-C drilling platform.IHS Markit said in July 2019 that the company had been mulling a MOPU unit for a while and that it was supposed to be bridge-connected to existing riser platform BYR-A.IHS also said that a new 12.7 km full well stream pipeline would be installed from BYDP-C to BYR-A, and modification and upgrade works would be carried out at existing facilities in the Bayan complex.Offshore Energy Today StaffSpotted a typo? Have something more to add to the story? Maybe a nice photo? Contact our editorial team via email. Also, if you’re interested in showcasing your company, product, or technology on Offshore Energy Today, please contact us via our advertising form where you can also see our media kit.last_img read more

Big cannabis in the UK: is industry support for wider patient access motivated by promises of recreational market worth billions?

first_imgBMJ 18 March 2020Family First Comment: The British Medical Journal has uncovered links between companies, campaign groups, and individuals lobbying for wider patient access to cannabis for medical use and a parallel campaign to create a lucrative recreational market for the drug in the UK.We always said to ‘follow the money’.We need a similar investigation in New Zealand.The BMJ has uncovered links between companies, campaign groups, and individuals lobbying for wider patient access to cannabis for medical use and a parallel campaign to create a lucrative recreational market for the drug in the UK, Jonathan Gornall reportsWhen Charlotte Caldwell arrived at Heathrow on 11 June 2018 with a six month supply of cannabis medication to treat her son Billy’s epilepsy, it was no coincidence that journalists and TV crews were on hand for the press conference that followed the inevitable seizure of the drug by customs officers.READ MORE: is the tobacco industry supporting wider access to medical cannabis?News Medical 18 March 2020A new study published in the BMJ reveals disturbing connections between organizations and groups that are lobbying for broader access to medical cannabis and those who are fighting for the legalization of recreational cannabis. This raises questions as to the reasons behind the industry’s support for measures that will make it easier for patients to gain access to medical cannabis – is it because of the knowledge that by so doing, they will also be able to market the drug for recreational use in the UK?The projected market for medical cannabis in the UK is estimated to be $1.3 billion, while that of recreational cannabis is thought to be still more significant, at about $1.7 billion.Linkages between recreational and medical cannabis promotersThe study report has two parts and is authored by investigative journalist Jonathan Gornall for the BMJ. The first part deals with the nexus between the commercial groups that are campaigning to allow new markets to be opened for recreational cannabis and those individuals or patient groups that are working for a broader range of access to cannabis for medical use.One such example he cites is that of Steve Moore, who was formerly the CEO of the Big Society Initiative headed by David Cameron. Moore helped Charlotte Caldwell, the mother of a severely epileptic boy called Billy Caldwell, to fly to Canada to obtain medical cannabis for her son from a company called Tilray. However, when she flew back, the drug was seized at customs – a predictable outcome that was duly captured in the press and used to promote the legalization argument. Moore has helped to promote Caldwell’s case. However, his interest in cannabis is not just to ensure it can be used medically in a broader setting.Moore is also a strategic counsel for the Center for Medicinal Cannabis, which is a trade organization representing businesses and investors that deal with medicinal cannabis products. It has members such as the Supreme Cannabis Company, a Canada-based organization. Again, he is strategic counsel for Volteface, which is an advocacy group that was founded in 2017, to campaign for the legalization of recreational cannabis. Volteface and the Center for Medicinal Cannabis are the brainchildren of and are funded by Paul Birch, while Tilray’s chief executive was once an advisor to Volteface. Birch has said he supports both medicinal and recreational cannabis use. At the same time, Moore suggests the legalization of cannabis would not benefit any legal cannabis companies, nor is the government considering such reforms. However, the moves made by their organizations and by big cannabis companies do not support this view.The implications of these connectionsIan Gilmore, who directs the Liverpool Centre for Alcohol Research, has sympathy for the plight of patients who would like to exploit the medical effects of cannabis and cannabis extracts in their particular situations, but cannot because it is not legally available.On the other hand, says Gilmore, there is the ever-present danger that false arguments from third parties will prompt such a move to legalize recreational cannabis. In his words, “We must not drift into the situation we found ourselves in with tobacco and alcohol, where global companies seeking to maximize their markets distorted the arguments, often through third parties. We must protect patients from having groups with conflicts of interest, building up unrealistic hopes.”Psychiatrist Marta Di Forti, who serves on the government task force to review the safety and effectiveness of cannabis in the treatment of pain, says she is unhappy about this association of patient cannabis groups and commercial cannabis companies. Her main concern is that this kind of lobbying could result in obtaining medicinal cannabis for many more medical conditions for which there is limited or no evidence of its efficacy.The problem with the current conversation on the medical use of cannabis is that it is making it easier and more normal to talk about cannabis in all kinds of settings where it would have been unacceptable earlier. This shift is acknowledged and welcomed by Stephen Murray, the executive director of Prohibition Partners. This is a private investment organization based in the UK, bent on making cannabis “more accessible and acceptable.” Murray observes that big investors in the corporate world are now becoming more and more involved in the spectrum of business opportunities that cannabis offers.The parent company of Murray’s firm, European Cannabis Holdings, recently split into a media wing and the Lyphe group of medical cannabis clinics, besides a medical cannabis ‘academy’ for clinicians, and an import-distribution company. The Lyphe group is also involved with Drug Science, headed by David Nutt, a sacked chairperson of the Advisory Council on the Misuse of Drugs. Drug Science is behind Project Twenty21, a huge trial of cannabis for seven different conditions from anxiety disorder to Tourette’s syndrome, to provide “largest body of evidence for the effectiveness and tolerability of medical cannabis” – but without a randomized controlled trial format, rather a general health questionnaire.Links between tobacco and medical cannabis researchThe second part of the report deals with the investigation of how the tobacco industry is funding research into medicinal cannabis. Here, Gornall examines the intricate network that has been woven between big commercial firms and the drive to legalize medical cannabis.In this second part, he uses Gavin Sathianathan as an example of the “new breed of cannabis entrepreneur.” Sathianathan is both the founder and the main shareholder of a private limited company based out of London, called Alta Flora, which markets “wellness products from natural sources.” In addition, he is one of the trustees managing United Patients Alliance (UPA), which is a cannabis support group led by patients; the chief executive of Forma Holdings which is an investment fund specializing in cannabis; and co-founder as well as director of Oxford Cannabinoid Technologies, which is a collaborative research effort including Oxford Universities.Among these companies, Oxford Cannabinoid Technologies is funded in part by Casa Verde Capital; an American venture capital firm co-founded by Snoop Dogg, US rapper, and influential promoter of recreational cannabis, and Imperial Brands (formerly known as Imperial Tobacco), the giant tobacco company. In defense, Oxford Cannabinoid Technologies’ spokesperson says that Imperial Brands holds only a small percentage of the company’s value and that the firm will not be interested in the UK recreational cannabis market even if restrictions in that country are relaxed.Twisting the narrativeHowever, Marta Di Forti is not convinced. She remembers the story of how tobacco and alcohol companies fed their own skewed version of facts to the public and the medical establishment through paid research and managed to get away with actively peddling deadly and addictive substances to young and old alike for decades before their bluff was called.Calling the fact that Imperial owns any stock in this cannabis research firm “dreadful and shocking”, Di Forti says, “It is always very dangerous to forget history and we are now seeing the sort of connections that we have seen happening before. We are lacking in funding for cannabis research from independent organizations such as the Wellcome Trust or the Medical Research Council. The result will be that more and more, you are going to see even prestigious and reputable academic institutions accepting money from some of these companies.”Ian Gilmore supports this stance: “It is vital that there is complete transparency in those making the case and supporting patient groups. We must not drift into the situation we found ourselves in with tobacco and alcohol, where global companies seeking to maximize their markets distorted the arguments, often through third parties. We must protect patients from having groups with conflicts of interest, building up unrealistic hopes.” up with family issues in NZ. Receive our weekly emails direct to your Inbox.last_img read more

Benitez backs Torres to lead Blues

first_img Benitez added: “He has to keep working in the same way and I think that with a pre-season he will have plenty of team to improve himself physically. It’s a question of keeping training the same way that he’s training now and with confidence, he has the potential.” Torres, who last found the net in the Premier League against Aston Villa in December, has cut a forlorn figure at times, ploughing a lone furrow up front. Benitez added: “When you see a striker that is not scoring as many goals as he wants to score, this can happen. Now he’s enjoying himself.” On his arrival, Benitez felt Chelsea could mount a Premier League title challenge, but a congested season – Sunday’s match will be the Blues’ 69th of the campaign – has played its part in ensuring that ambition was never close to being fulfilled. To take on Manchester United, Benitez felt Chelsea needed to sign players in January and augment a squad which is packed with quality, but short of numbers in a transitional period, following the departures of the likes of Didier Drogba. Benitez refused to criticise the board for not weighing into the transfer market, with striker Demba Ba the one major January addition, but he has fulfilled his brief by delivering a Champions League return. “Always [it] can be better,” Benitez said. “We cannot change what happened and we have to think of the future as a positive. The club had an idea. We have been successful in one of the big competitions and we are virtually qualified for the Champions League. So in the end it was fine.” Rafael Benitez is confident striker Fernando Torres can return to being an unstoppable force as the interim boss prepares for his final competitive game at Chelsea. Torres has endured a challenging two-and-a-half year spell at Stamford Bridge since his £50million move from Liverpool in January 2011, but netted six goals in six Europa League appearances this season, including in the final as the Blues beat Benfica in the Amsterdam final on Wednesday. “It’s more than just me,” said Benitez, when asked about Torres’ improvement, before he cited assistant coaches Steve Holland, Boudewijn Zenden and fitness coaches Paco de Miguel and Chris Jones for their efforts. “They have improved him. He has more pace, more confidence and he can score important goals for us.” center_img Press Associationlast_img read more

Indians Have Most Positive View of US and Trump Trump in Asia

first_imgIndians have a more positive opinion about the Donald Trump administration than other countries in the region, according to a recent  survey. The favorable view of Indians comes despite the Trump government’s decision to have stricter regulations on H-1B visa policies.Nearly 71 percent of Indians believe that the U.S. has a positive influence even with Trump as president. By contrast just 11 percent of Koreans, 15 percent of Chinese, 16 percent of Australians, 19 percent of Japanese and 29 percent of Indonesians felt the U.S. has a positive impact.Indians consider the US to be the most influential government in the world in terms of social, political, economic and financial growth and dependence, according to the survey on public opinion conducted by Australian institute Perth U.S. Asia Center in May, which was released in New Delhi by former Australian Defence Minister Stephen Smith.The survey further showed that the Indian opinion on the United States differs widely from that held by people in Japan, China, Australia, South Korea, and Indonesia. The survey concluded that “Indian respondents are the most optimistic about the U.S. with 61% believing that its best years are ahead of it.”“There’s no doubt that the rise of the Trump presidency  has seen a diminution of the US influence in the rest of Asia. On the other hand, if you look at the US through the eyes of India, it is the most robust country in its view of US influence. In terms of our results, Indians take a very positive view of the current position of the US and of its future role here,” Smith told The Hindu .The survey asked for people’s views on the role played by America in the Indo-Pacific region.“India is really an outlier, on every question they have a more optimistic view of the United States as compared with even allies like Japan, Australia and Korea. Japanese who are the closest allies were very pessimistic that the U.S. has its best days behind it. In India, 61% say they are ahead,” Gordon Flake, the CEO of the Perth U.S. Asia Centre, was quoted as saying by the Hindu.The results of the survey are further bolstered by figures that indicate that India has the highest number of ‘Trump’ branded real-estate projects outside North America, which have been franchised to companies in India. For instance, the Trump Towers at Kalyani Nagar in Pune, developed by the Chordias of Panchshil Realty, houses 44 luxury condominiums. Then there is the under-development The Park, a 75-storey tower coming up at Parel in Mumbai from the Lodha Group.The survey concludes: “The overall goodwill and optimism concerning the United States appears to translate into considerable and broad enthusiasm for the India-United States relationship with 65% of Indian respondents believing the United States has a positive impact on India.” Indo-US Relations in the PastWhile Indians are now viewing the US in a positive manner, it was not the case earlier. A century ago, only 2,031 Indians were approved as legal permanent residents of the United States, according to The Other One Percent, a book by Sanjoy Chakravorty, Devesh Kapur and Nirvikar Singh that delves into the story of Indians’ success as an immigrant group in American history.The book reveals that this number grew to 4,664 within the next 10 years, with California being the most preferred ground for Indians. This boost in Indian population was aided by the fact that migrants from the country were denied entry to Canada.The rapid rise in the Indian population soon resulted in dissatisfaction among the local workers, who saw the influx as a threat to their livelihood. They protested against the Indian migrants, calling them ‘dirty’, ‘untrustworthy’, ‘insolent’ and ‘unlawful’, and labelling them as ‘Hindoos’. Thousands of Indians were mobbed out within a few months.In the recent past, the revised H-1B visa policy also had adverse effects on the Indian IT sector. According to the revised policies, only the high-skilled employees can procure the visa if their salary falls in the $1,00,000 – $1,30,000 bracket.Despite all the ups and downs in the past, the survey conducted by the Perth U.S Asia Centre states that most Indians are hopeful for better relations between the two countries. The Japanese, on the other hand, held the most pessimistic opinion about Trump’s presidency while most other countries thought China was the country that could have the most impact on Asia’s future. Related Itemslast_img read more